Popular terms

G Proteins topics
G Proteins
Antibodies
Immunoglobulin
Metalloprotein
Chemotherapeutic Agent
Kinase Inhibitor
Tetrapeptide
Apoptosis Protein
Topoisomerase
Peptidomimetic
Fractionation
Medical Treatment
Chromatograph
Encapsulation
Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Proteins patents



      

This page is updated frequently with new G Proteins-related patent applications.




Date/App# patent app List of recent G Proteins-related patents
07/14/16
20160202234 
 Method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation patent thumbnailMethod for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation
The invention relates to a method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation. Said method comprises: a) sampling, in at least one area of the body of the person, the follicles or bulbs of head and/or body hair of the person; b) extracting proteins from cells of said sampled hair bulbs or follicles, wherein said proteins, including proteins from the atm system, are subjected to phosphorylation and/or acetylation induced by ionizing radiation; and c) analyzing at least two types of extracted proteins and interpreting the analysis results in order to determine the irradiation dose in the or each sampling area..
Acubens


07/14/16
20160201031 
 Composition and methods for culturing cells patent thumbnailComposition and methods for culturing cells
The present disclosure provides compositions for in vitro culture of cells. The present disclosure provides methods for in vitro culture of cells.
The Regents Of The University Of California


07/14/16
20160200847 
 Clickable polymers and gels for  microarray and other applications patent thumbnailClickable polymers and gels for microarray and other applications
Fabrication of arrays, including glycan arrays, that combines the higher sensitivity of a layered si—sio2 substrate with novel immobilization chemistry via a “click” reaction. The novel immobilization approach allows the oriented attachment of glycans on a “clickable” polymeric coating.

07/14/16
20160200823 
 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof patent thumbnailBinding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a cd154 (cd40l) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized fab fragment comprising a variable heavy chain sequence according to seq id no: 1 and comprising a variable light chain sequence according to seq id no: 2 specifically binds.
Biogen Idec Ma Inc.


07/14/16
20160200813 
 Lrp-8 binding proteins patent thumbnailLrp-8 binding proteins
The disclosure provides binding proteins that specifically bind to lrp-8 and optionally cross the blood brain barrier (bbb), localize to the brain and/or localize to the spinal cord.. .
Abbvie Inc.


07/14/16
20160200811 
 Dual variable region antibody-like binding proteins having cross-over binding region orientation patent thumbnailDual variable region antibody-like binding proteins having cross-over binding region orientation
The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins..
Sanofi


07/14/16
20160199443 
 Polypeptide targeting to mitochondria patent thumbnailPolypeptide targeting to mitochondria
Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a dna-binding polypeptide, fused to a mitochondrial targeting sequence (mts) and a nuclear export signal (nes), and the encoded proteins.
Medical Research Council


07/14/16
20160198737 
 Method for recovering proteins from waste water discharged during process of producing fish meat processed product patent thumbnailMethod for recovering proteins from waste water discharged during process of producing fish meat processed product
According to the present invention, a method for recovering useful fish meat proteins from waste water generated during fish paste or fishmeal production is provided. The provided is a method for recovering water-soluble proteins from fish paste leaching waste water or stick water, comprising: adjusting the ph of fish paste leaching waste water or stick water to 4.5-5.5 to insolubilize water-soluble proteins; heating the insolubilized proteins to 30° c.
Maruha Nichiro Corporation


07/07/16
20160195525 
 Diagnosis and treatment of mycobacteria infections patent thumbnailDiagnosis and treatment of mycobacteria infections
The invention provides isolated, purified, recombinant receptor binding proteins gp-6, gp-10 and gp-31 from mycobacterium phage l5, and methods for producing these recombinant receptor binding proteins. The invention also provides the use of recombinant receptor binding proteins, including gp-6, gp-10 and gp-31, as probes for the identification and diagnosis of mycobacterium infections and conditions caused by mycobacterium.
The Governors Of The University Of Alberta


07/07/16
20160194606 
 Methods for inducing the differentiation of blood monocytes into functional dendritic cells patent thumbnailMethods for inducing the differentiation of blood monocytes into functional dendritic cells
Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins.
Yale University


07/07/16
20160194409 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


07/07/16
20160194397 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


07/07/16
20160193358 

Antigen binding proteins


The present invention concerns antigen binding proteins and fragments thereof which specifically bind b cell maturation antigen (bcma), particularly human bcma (hbcma) and which inhibit the binding of baff and april to the bcma receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods..
Glaxo Group Limited


07/07/16
20160193150 

Reducing or non-reducing polynucleotide polymer for drug delivery and preparing same


The present invention relates to a reducing or non-reducing polynucleotide polymer for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer. The present invention relates to a drug delivery carrier for delivering proteins or peptides to a targeted area through electrostatic attraction, by obtaining a negatively (−) charged polymer by using nucleotides to synthesize the reducing or non-reducing polymer, which is easily breakable due to disulfide bonds, and then bonding the negatively (−) charged polymer with a positively (+) charged protein or peptide, wherein a polymer derived from a non-viral drug delivery carrier containing the novel reducing or non-reducing polymer is capable of effectively enabling escape of a drug, delivered by means of proton buffering activity, from an endosome to other organelles in a cell..
Utah-inha Dds & Advanced Therapeutics Research Center


07/07/16
20160192697 

Protein-enriched tobacco-derived composition


The present disclosure describes methods of obtaining and/or deriving proteins from plants of the nicotiana species and methods for incorporation of such proteins into various products. For example, a method for obtaining a protein-enriched material from a plant of the nicotiana species or portion thereof is provided, comprising: extracting one or more proteins from the plant material into a solvent to form a liquid protein-containing extract; separating a solid extracted plant material from the liquid protein-containing extract; clarifying the liquid protein-containing extract to form a clarified protein-containing extract and a solids fraction; and treating the clarified protein-containing extract so as to provide a protein-enriched material comprising at least about 60% protein by weight..
R.j. Reynolds Tobacco Company


06/30/16
20160187357 

Compositions and methods for increasing bone mineralization


A novel class or family of tgf-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules..

06/30/16
20160186157 

Intein-modified enzymes, their production and industrial application


A method of predicting an intein insertion site in a protein that will lead to a switching phenotype is provided. The method includes identifying a plurality of c/t/s sites within the protein; selecting from the plurality of c/t/s/sites those that are ranked 0.75 or higher by a support vector machine, within ten angstroms of the active site of the protein, and at or near a loop-β-sheet junction or a loop-α-helix junction.

06/30/16
20160184413 

Formulation for stabilizing proteins, which is free of mammalian excipient


The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, wherein the formulation is free of stabilising proteins.. .

06/23/16
20160177300 

Means and methods for the generation of mammalian producer cells for the production of recombinant proteins


The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.. .

06/23/16
20160176971 

Methods and compositions relating to anti-il-21 receptor antibodies


The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .

06/23/16
20160176958 

Tnf-alpha binding proteins


Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (tnf-α), e.g., human tnf-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies..

06/16/16
20160168593 

Methods and compositions for enhancing targeted transgene integration


Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of r loop formation or inhibitors of r-loop repair and/or one or more up-regulators of the tc-ner pathway to the target cell.. .
Sangamo Biosciences, Inc.


06/16/16
20160168559 

Biocatalytical composition


The present invention relates to means and methods for protecting proteins and protein-type compounds in industrial and other applications. In particular, the invention provides a composition comprising at least one protein or protein-type compound immobilized at the surface of a solid carrier embedded in a protective material.
Inofea Gmbh


06/16/16
20160168264 

Antibodies directed to her-3 and uses thereof


The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


06/16/16
20160168205 

Methods and compositions for labeling polypeptides


Synthesis of many proteins is tightly controlled at the level of translation and plays an essential role in fundamental processes such as cell growth and proliferation, signaling, differentiation or death. Methods that allow imaging and identification of nascent proteins allow for dissecting regulation of translation, both spatially and temporally, including in whole organisms.
President And Fellows Of Harvard College


06/16/16
20160168194 

Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation


06/16/16
20160168154 

Inhibitors of transcription factors and uses thereof


The present invention provides novel compounds of any one of formulae (i) to (iv), and pharmaceutically compositions thereof. Compounds of any one of formulae (i) to (iv) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (bets)).
University Of Massachusetts


06/16/16
20160166663 

Vaccine formulations that induce a th2 immune response


The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


06/09/16
20160160268 

Amdinocillin for rapid determination of susceptibility to beta-lactam antibiotics


Described are methods for detecting susceptibility of a specimen to antibiotics, and particularly for enhancing such susceptibility testing for beta lactam antibiotics and antibiotics that bind to penicillin-binding proteins. The method comprises contacting the specimen with an oligonucleotide probe that specifically hybridizes with a target nucleic acid sequence region of ribosomal rna.
United States Government Represented By The Department Of Veterans Affairs


06/09/16
20160160048 

Polymers and plastics derived from animal proteins


The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
The Governors Of The University Of Alberta


06/09/16
20160159923 

Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


06/09/16
20160159865 

Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof


Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland


06/09/16
20160159856 

Affinity tags and processes for purifying and immobilizing proteins using same


The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag.. .
University Of Washington Through Its Center For Commercialization


06/02/16
20160153911 

Instant view of protein bands


Apparatus, reagents, pre-treated proteins and methods for dying proteins in electrophoresis run gels, and for instantly viewing such dyed protein samples in an electrophoresis gel. A protein mixing solution containing a fluorescence dye is mixed with a protein sample so that fluorescence dyes within the protein mixing solution conjugate to proteins within the protein sample.

06/02/16
20160153872 

System and retrieval treatment of proteins in formalin-fixed paraffin-embedded tissue section


A protein retrieval treatment system used for activating proteins contained in a deparaffinized tissue section obtained by removing paraffin from a formalin-fixed paraffinembedded tissue section. The protein retrieval treatment system includes: a dispensing unit for dispensing a retrieval treatment solution over a dispensing area including a measurement area on the deparaffinized tissue section; and a moist-heat treatment unit for heating, in a saturated water vapor, the deparaffinized tissue section with the dispensing area covered with the retrieval treatment solution..
Shizuoka Prefecture


06/02/16
20160152728 

Antibody binding sites specific for egfrviii


This application describes binding proteins that specifically bind to egfrviii and multispecific binding proteins that specifically bind to egfrviii and cd3. Further described is a multispecific tandem diabody that binds to egfrviii and cd3.
Affimed Gmbh


06/02/16
20160152725 

Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide


Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv (scfv) fragments, as well as chimeric antigen receptors.
Memorial Sloan-kettering Cancer Center


06/02/16
20160152700 

Antigen binding proteins capable of binding thymic stromal lymphopoietin


The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (tslp), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-tslp antibodies and derivatives of such antibodies.
Amgen Inc.


05/26/16
20160147936 

Rational solubilising proteins


A method and data processing system for identifying mutations or insertions that alter a property such as the solubility or aggregation propensity of an input polypeptide chain. The method comprises inputting a sequence of amino acids and a structure for said sequence for said target polypeptide chain; calculating a structurally corrected solubility or aggregation propensity profile for said target polypeptide chain; selecting, using said calculated profile, regions within said target polypeptide chain; identifying at least one position within each selected region suitable for mutations or insertions; generating a plurality of mutated sequences by mutations or insertions at least one identified position; and predicting a value of the solubility or aggregation propensity for each of the plurality of mutated sequences whereby any alteration to the solubility or aggregation propensity of the input polypeptide chain is identified.
Cambridge Enterprise Limited


05/26/16
20160146828 

Chemistry, systems and methods of translocation of a polymer through a nanopore


Embodiments disclosed herein are directed to recognition tunneling systems, methods and devices, and more particularly, to chemical reactions for selectively labeling proteins and peptides and placing protein and/or peptides into, or onto a nanopore formed in a solid support and threading such in and/or through the nanopore, with such nanopores, in some embodiments, including a molecular motor to pull or otherwise force the protein/peptide through the nanopore.. .
Arizona Board Of Regents Acting For And On Behalf Of Arizona State University


05/26/16
20160146827 

Genetically encoded sensors for imaging proteins and their complexes


Isolated truncated and mutated sensor proteins derived from flavoproteins that are 12-20 kda or less, genetically encoded for detection and imaging of protein complexes having long fluorescent lifetimes that can be 4.0 ns or greater.. .
President And Board Of Trustees Of Santa Clara College


05/26/16
20160145351 

Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof


The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.


05/26/16
20160145333 

Cb-1 receptor antigen-binding proteins and uses thereof


This disclosure relates to cb1 receptor antigen-binding proteins, e.g. Antibodies and methods of using the cb1 receptor antibodies.
Amgen Inc.


05/26/16
20160145332 

Il-21 binding proteins and uses thereof


The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (il-21) and uses thereof, e.g., in therapy.. .
Monash University


05/26/16
20160145322 

Human antibodies binding to rsv g proteins


The disclosure provides isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv.. .
Crucell Holland B. V.


05/19/16
20160138034 

Novel genes involved in biosynthesis


The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited


05/19/16
20160137739 

Oncostatin m receptor antigen binding proteins


The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.


05/19/16
20160137708 

Il-1 family variants


The present invention provides compositions and methods relating to il-1rrp2 requiring proteins.. .
Amgen Inc.


05/19/16
20160136239 

Method for producing autologous proteins


A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Arthrogen Gmbh


05/12/16
20160132634 

Computer-implemented methods of determining protein viscosity


The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag


05/12/16
20160130568 

Thermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods


Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc.


05/12/16
20160130332 

Antibodies to human signal peptide-containing proteins


The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


05/12/16
20160130327 

Cmv neutralizing antigen binding proteins


The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (cmv). Also encompassed by the invention are antigen binding proteins that have been humanized.
Board Of Regents Of The University Of Texas System


05/05/16
20160123956 

Modified membrane spanning proteins and methods for the preparation and use thereof


In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like.
Abilita Bio, Inc.


05/05/16
20160122439 

Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof


Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant dll4 and/or vegf expression or activity.. .
Abbvie Inc.


05/05/16
20160122437 

Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


04/28/16
20160115210 

Colorimetric and fluorescent proteins


The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.. .
Board Of Trustees Of Michigan State University


04/21/16
20160109424 

Swath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products


Systems and methods are provided for detecting host cell contaminants in a protein biotherapeutic product using sequential windowed acquisition tandem mass spectrometry. Sequential windowed acquisition is performed on a protein biotherapeutic product sample by sequentially stepping a precursor mass window across a mass range, fragmenting transmitted precursor ions of each stepped precursor mass window, and analyzing product ions produced from the fragmented transmitted precursor ions.

04/21/16
20160106850 

Methods and compositions for wound treatment


The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .

04/14/16
20160102150 

Plasma kallikrein binding proteins


Plasma kallikrein binding proteins and methods of using such proteins are described.. .

04/07/16
20160097053 

Yeast promoters from pichia pastoris


In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


04/07/16
20160097050 

Devices and methods for display of encoded peptides, polypeptides, and proteins on dna


A novel method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the dna encoding them. Proteins or peptides can be generated by in vitro translation of dna templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their dna templates.
The Board Of Trustees Of The Leland


04/07/16
20160095917 

Dps fusion proteins for use in vaccines and diagnostics


Novel nanoparticle fusion proteins comprising proteins or peptides fused to dps (dna binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.. .
Kj Biosciences Llc


04/07/16
20160095313 

Antimicrobial compositions and methods


The present invention is generally related to a product and process to reduce the microbial contamination on organic matter, such as processed meat, fruits and vegetables, plant parts, inanimate surfaces such as textiles and stainless steel, and in the mouth or on dental products. In particular, the invention is related to a product and process to disinfect surfaces using an antimicrobial composition containing an antimicrobial lipid, an enhancer selected from the group consisting of bacteriocins, antimicrobial enzymes, sugars, sugar alcohols, iron-binding proteins and derivatives thereof, siderophores, and combinations thereof, and optionally a surfactant..
3m Innovative Properties Company


03/31/16
20160090414 

Binding proteins specific for insulin-like growth factors and uses thereof


Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Medimmune Limited


03/31/16
20160090404 

Modified biotin-binding protein, fusion proteins thereof and applications


The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen.
Children's Medical Center Corporation


03/31/16
20160089445 

Derivatisation of biological molecules


The polymers are particularly suitable for derivatising proteins, such as interferon-α.. .

03/24/16
20160082083 

Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity


Insulin-like growth factor binding proteins (igfbps) and variants thereof, including igfbp-1, igfbp-2, igfbp-3, igfbp-4, igfbp-5, igfbp-8 and the c-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin b activity.. .
National Research Council Of Canada


03/24/16
20160081348 

Decontamination solution and its use for denaturation, modification, degradation, solubilisation and removal of proteins, nucleic acid molecules and microorganisms


The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms are applied by spraying, rubbing or immersion of contaminated surfaces thereby destroying, solubilizing inactivating and removing proteins and nucleic acids.
Multibind Biotec Gmbh


03/17/16
20160076052 

Design synthetic genes


The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a gc content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a gc content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes..
Jnc Corporation


03/17/16
20160075773 

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration


The present application describes rgm a binding proteins, particularly monoclonal antibodies, and in particular cdr grafted, humanized versions thereof, which have the ability to bind to rgm a and prevent binding of rgm proteins to rgm a receptor and other rgm a binding proteins, and therefore neutralize the function of rgm a, for use in the treatment of retinal nerve fiber layer (rnfl) degeneration as well as methods of therapeutically or prophylactically treating a mammal against rnfl degeneration.. .
Abbvie Deutschland Gmbh & Co. Kg


03/17/16
20160075743 

Methods and materials for encapsulating proteins


The invention provides a method for encapsulating a protein of interest, the method comprising the step of expressing a fusion protein comprising an n-terminal region of a rearrangement hot spot (rhs)-repeat-containing protein fused to the protein of interest. The invention further provides applications for the encapsulation, release and delivery of the protein of interest.
Agresearch Ltd


03/17/16
20160074373 

Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs


Compositions and methods concern organic molecules that bind to human atox1 and ccs at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


03/10/16
20160069893 

Methods and compositions for analyzing proteins


Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs.
Monogram Biosciences, Inc.


03/10/16
20160068614 

Bonding tissues and cross-linking proteins with naphthalimide compounds


Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together.
Alumend, Llc


03/10/16
20160067674 

Ligands and methods for isolating or removing proteins


The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation.
Previpharma Ag


03/10/16
20160066611 

Process for preparing a pumpable broth composition


Disclosed here is a process for preparing a concentrated liquid composition (such as a broth) from poultry or other meat sources without the use of any enzymes. The resultant composition may have high content of solids but are pumpable or pourable and have relatively long shelf life at room temperature.
International Dehydrated Foods, Inc.


03/03/16
20160063177 

Automated computational enzyme identification and design


The invention provides computational methods for engineering, selecting, and/or identifying proteins with a desired activity. Further provided are automated computational design and screening methods to engineer proteins with desired functional activities including, but not limited to ligand binding, catalytic activity, substrate specificity, regioselectivity and/or stereoselectivity..

03/03/16
20160060662 

Desaturases of a green microalga and uses thereof


Isolated proteins which are at least partially encoded by polynucleotide sequences encoding novel desaturases are provided together with a composition which includes these isolated proteins. A transgenic plant, a transgenic alga, or a transgenic seed transformed by the polynucleotides encoding proteins which are at least partially encoded by novel desaturases are also provided.
Ben Gurion University Of The Negev Research And Development Authority


03/03/16
20160060656 

Methods and compositions for the treatment of lysosomal storage diseases


Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.. .
Sangamo Biosciences, Inc.


03/03/16
20160060640 

Coryneform bacterium and producing heterologous fusion proteins


The present invention provides a coryneform bacterium having an ability to produce a heterologous fusion protein by secretory production, which has been modified to express a genetic construct for secretory production of the heterologous fusion protein encoding at least a heterologous fusion protein comprising an extein and an intein having an activity of acyl rearrangement. The method for producing proteins modified at the c-terminus is also provided..
Ajinomoto Co., Inc.


03/03/16
20160060591 

Feed media


The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods..
Amgen Inc.


03/03/16
20160060359 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


03/03/16
20160060332 

Therapeutic dll4 binding proteins


Improved dll4 binding proteins are described, including antibodies, cdr-grafted antibodies, human antibodies, and dll4 binding fragments thereof, proteins that bind dll4 with high affinity, and dll4 binding proteins that neutralize dll4 activity. The dll4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant dll4 expression or activity such as autoimmune disorders including multiple sclerosis..
Abbvie Inc.


03/03/16
20160060327 

Anti-infective binding proteins that bind aip2


There is disclosed compositions and methods relating to or derived from anti-aip2 antibodies. More specifically, there is disclosed fully human antibodies that bind aip2, aip2-binding fragments and derivatives of such antibodies, and aip2-binding polypeptides comprising such fragments.
Sorrento Tharapeutics, Inc.


03/03/16
20160058863 

Low viscosity concentrated protein dispersions


Disclosed herein are, inter alia, low viscosity dispersions comprising proteins and viscosity lowering agents; pharmaceutical compositions comprising low viscosity dispersions; and methods of making and using the pharmaceutical compositions and low viscosity dispersions.. .
Board Of Regents, The University Of Texas System


03/03/16
20160057979 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


02/25/16
20160054327 

Rapid protein labeling and analysis


The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein.
Life Technologies Corporation


02/25/16
20160053300 

Nanopore biosensors for detection of proteins and nucleic acids


Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties..
Katholieke Universiteit Leuven


02/25/16
20160053298 

Methods for identifying proteins and compounds that modulate the activity of otub1


The present invention describes that otub1 cleavage of k48 poly-ubiquitin is stimulated by a select subset of e2 enzymes, and that this stimulation is regulated by the ubiquitin-charged state of the e2 and free ubiquitin. Structural and biochemical studies of otub1 and ubch5b show that the e2 stimulates binding of the polyubiquitin substrate by contacting the otub1 n-terminal ubiquitin-binding helix.
The Johns Hopkins University


02/25/16
20160053014 

Antigen binding proteins that bind cxcr5


There is disclosed compositions and methods relating to or derived from anti-cxcr5 antibodies. More specifically, there is disclosed fully human antibodies that bind cxcr5, cxcr5-binding fragments and derivatives of such antibodies, and cxcr5-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


02/25/16
20160053013 

Antigen binding proteins that bind cxcr3


There is disclosed compositions and methods relating to or derived from anti-cxcr3 antibodies. More specifically, there is disclosed fully human antibodies that bind cxcr3, cxcr3-binding fragments and derivatives of such antibodies, and cxcr3-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


02/25/16
20160053000 

Apelin antigen-binding proteins and uses thereof


This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis.
Amgen Inc.




G Proteins topics: G Proteins, Antibodies, Immunoglobulin, Metalloprotein, Chemotherapeutic Agent, Kinase Inhibitor, Tetrapeptide, Apoptosis Protein, Topoisomerase, Peptidomimetic, Fractionation, Medical Treatment, Chromatograph, Encapsulation, Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8169

4685

2 - 1 - 101